Table 1 Demographic and disease characteristics of the JDM cohort
Frequency (n) | Percentage | |
|---|---|---|
Sample size | 68 | |
Sex | ||
Female | 57 | 16.2% |
Male | 11 | 83.8% |
Race/Ethnicity | ||
White | 51 | 75.0% |
Hispanic | 13 | 19.1% |
African American | 2 | 2.9% |
Others | 2 | 2.9% |
Myositis specific antibodies | ||
P155/140 | 28 | 41.2% |
MJ | 2 | 2.9% |
Mi2 | 5 | 7.4% |
MDA5 | 2 | 2.9% |
Others or multiple MSAs | 5 | 7.4% |
Negative | 21 | 30.8% |
Not done | 5 | 7.4% |
Treatment | ||
Oral steroid | 68 | 100% |
Intravenous steroid | 64 | 94.1% |
Methotrexate | 63 | 92.6% |
Intravenous immunoglobulin | 8 | 11.8% |
Hydroxychloroquine | 41 | 60.3% |
Cyclosporine | 12 | 17.6% |
Mycophenolate | 26 | 38.2% |
Disease course | ||
Monocyclic short | 12 | 17.6% |
Monocyclic long | 29 | 42.6% |
Polycyclic | 14 | 20.6% |
Chronic | 13 | 19.1% |